肺癌中PD-L1表达和调节性T细胞浸润的关系及意义

摘要

目的：探讨非小细胞肺癌(non-small cell lung cancer, NSCLC)中程序性死亡受体配体1(programmed death receptor ligand 1, PD-L1)表达和调节性T细胞(regulatory T cell, Treg)浸润的关系及临床意义。方法采用免疫组化法检测78例NSCLC组织中PD-L1表达和Treg浸润情况,分析二者之间的相关性及与NSCLC临床病理特征的关系。结果肺癌组织中PD-L1的表达显著高于癌旁组织(52．5% vs 6．4%),肺癌组织中 Treg浸润亦明显高于癌旁组织[(18．63±16．67)个/HPF vs (2．96±2．97)个/HPF]。晚期肺癌组织中PD-L1的表达高于早期肺癌组织(70．0% vs 41．7%),晚期肺癌组织中Treg浸润亦明显高于早期肺癌组织(73．3% vs 35．4%),有淋巴结转移组中PD-L1表达和Treg浸润均明显高于无淋巴结转移组,PD-L1表达和Treg浸润程度与淋巴结转移及临床分期相关(P<0．05)。肺癌组织中PD-L1表达和Foxp3+Treg的浸润密度呈正相关(rs =0．611,F=78．82,P=0．023)。结论肺癌微环境中PD-L1表达和Treg浸润呈正相关,二者可能共同参与肺癌的进展和免疫逃逸。%Purpose To investigate relationship between PD-L1 molecule expression and Treg infiltration in non-small cell lung cancer ( NSCLC) tissue and to explore their clinical significance. Methods Immunohistochemistry was used to detect the PD-L1 molecules expression and Treg infiltration of 78 NSCLC tissues. The relationship among PD-L1 expression, Treg infiltration and clinic-pathological parameters was analyzed in the patients. Results PD-L1 molecule was highly expressed in lung cancer tissues than adjacent tissues (52. 5% vs 6. 4%), and same to Foxp3 +Treg (18. 63 ± 16. 67)/HPF vs (2. 96 ± 2. 97)/HPF. There was close relationship between PD-L1 expression and Treg infiltration with lymph node metastasis and clinical stage of patients, but was no statistical correlation with patient’ s age, gender, histological type and degree of differentiation of the tumor cells. PD-L1 expression was significantly higher in advanced stage than that in early stage (70. 0% vs 41. 7%) and same to Treg infiltration (73. 3% vs 35. 4%). There were also signif-icantly higher infiltration with lymph node metastasis than that without metastasis. In addition, PD-L1 molecule expression and Foxp3 +Treg infiltration were positively correlated (rs =0. 611, F=78. 82, P=0. 023). Conclusion There was strong relationship among PD-L1 expression, Treg infiltration and disease progress in lung cancer patients, and they possibly participate in the progression and immune escape of lung cancer.